CN Patent

CN114437058A — 氘代hpk1激酶抑制剂及其制备方法和应用

Assigned to Zhuhai Woo Biological Science And Technology Co ltd · Expires 2022-05-06 · 4y expired

What this patent protects

本发明提供了一种通式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物及其制备方法和应用，特别是通式为Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物作为HPK1激酶抑制剂在预防和/或治疗肿瘤、由病原体感染引起或病原体感染相关的疾病中的应用。上述通式Ⅰ的化合物含有至少一个氘原子，其在动物体内稳定性高，生物利用度佳。

USPTO Abstract

本发明提供了一种通式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物及其制备方法和应用，特别是通式为Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物作为HPK1激酶抑制剂在预防和/或治疗肿瘤、由病原体感染引起或病原体感染相关的疾病中的应用。上述通式Ⅰ的化合物含有至少一个氘原子，其在动物体内稳定性高，生物利用度佳。

Drugs covered by this patent

Xalkori (crizotinib) · Pfizer

Patent Metadata

Patent number: CN114437058A
Jurisdiction: CN
Classification: —
Expires: 2022-05-06
Drug substance claim: No
Drug product claim: No
Assignee: Zhuhai Woo Biological Science And Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.